• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钆塞酸增强磁共振成像预测丙型肝炎病毒治疗期间格卡瑞韦引起的高胆红素血症。

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment.

机构信息

Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-ku, Tokyo, 177-8521, Japan.

Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, 1715 Kamagari, Inzai, Chiba, 270-1694, Japan.

出版信息

Sci Rep. 2022 May 12;12(1):7847. doi: 10.1038/s41598-022-11707-6.

DOI:10.1038/s41598-022-11707-6
PMID:35552472
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9098462/
Abstract

Glecaprevir is a substrate for organic anion-transporting polypeptide (OATP) 1B1/1B3, which transports bilirubin. Hyperbilirubinemia is an adverse event during anti-hepatitis C virus treatment with glecaprevir and pibrentasvir. Gadoxetic acid is also transported by OATP1B1/1B3, and we aimed to evaluate whether gadoxetic acid-enhanced magnetic resonance (MR) imaging was associated with glecaprevir trough concentrations (C). We further determined whether this was predictive of hyperbilirubinemia development in a cohort of 33 patients. The contrast enhancement index (CEI), a measure of hepatic enhancement effect on the hepatobiliary image, was assessed. Glecaprevir C was determined 7 days after administration. Five of the 33 patients (15%) developed Common Terminology Criteria for Adverse Events grade ≥ 2 hyperbilirubinemia. We found a negative relationship between CEI and C (r = - 0.726, p < 0.001). The partial correlation coefficient between CEI and C was - 0.654 (p < 0.001), while excluding the effects of albumin, FIB-4 index, and indirect bilirubin at baseline. The C was significantly higher in patients with hyperbilirubinemia than in those without (p = 0.008). In multivariate analysis, CEI ≤ 1.71 was an independent factor influencing the development of hyperbilirubinemia (p = 0.046). Our findings indicate that gadoxetic acid MR imaging can help predict glecaprevir concentration and development of hyperbilirubinemia.

摘要

格卡瑞韦是有机阴离子转运多肽(OATP)1B1/1B3 的底物,后者可转运胆红素。在接受格卡瑞韦和哌仑他韦治疗丙型肝炎病毒期间,高胆红素血症是一种不良事件。钆塞酸同时也由 OATP1B1/1B3 转运,我们旨在评估钆塞酸增强磁共振(MR)成像是否与格卡瑞韦谷浓度(C)相关。我们进一步确定在 33 例患者队列中,这是否与高胆红素血症的发生有关。评估了对比增强指数(CEI),这是衡量肝胆图像上肝增强效果的指标。在给药后 7 天测定格卡瑞韦 C。33 例患者中有 5 例(15%)发生常见不良事件术语标准≥2 级高胆红素血症。我们发现 CEI 与 C 之间存在负相关(r=-0.726,p<0.001)。CEI 与 C 的偏相关系数为-0.654(p<0.001),而在排除基线白蛋白、FIB-4 指数和间接胆红素的影响后。高胆红素血症患者的 C 明显高于无高胆红素血症患者(p=0.008)。在多变量分析中,CEI≤1.71 是影响高胆红素血症发生的独立因素(p=0.046)。我们的研究结果表明,钆塞酸 MR 成像可以帮助预测格卡瑞韦浓度和高胆红素血症的发生。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d4/9098462/ce09ebc5ee03/41598_2022_11707_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d4/9098462/a8a2ef08b391/41598_2022_11707_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d4/9098462/ce09ebc5ee03/41598_2022_11707_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d4/9098462/a8a2ef08b391/41598_2022_11707_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d4/9098462/ce09ebc5ee03/41598_2022_11707_Fig2_HTML.jpg

相似文献

1
Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment.钆塞酸增强磁共振成像预测丙型肝炎病毒治疗期间格卡瑞韦引起的高胆红素血症。
Sci Rep. 2022 May 12;12(1):7847. doi: 10.1038/s41598-022-11707-6.
2
Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.钆塞酸增强磁共振成像预测丙型肝炎治疗中帕立瑞韦引起的高胆红素血症。
PLoS One. 2018 Apr 30;13(4):e0196747. doi: 10.1371/journal.pone.0196747. eCollection 2018.
3
Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study.钆塞酸增强磁共振成像预测丙型肝炎病毒治疗期间simeprevir诱导的高胆红素血症:一项初步研究。
J Clin Pharmacol. 2017 Mar;57(3):369-375. doi: 10.1002/jcph.811. Epub 2016 Sep 22.
4
Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.多中心丙型肝炎感染肾脏移植研究(MYTHIC):用格卡瑞韦哌仑他韦联合治疗丙型肝炎病毒感染的已故供者来源移植肾受者的开放性研究。
J Am Soc Nephrol. 2020 Nov;31(11):2678-2687. doi: 10.1681/ASN.2020050686. Epub 2020 Aug 25.
5
Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis.药物性肝损伤由 glecaprevir/pibrentasvir 治疗慢性丙型肝炎感染引起:系统评价和荟萃分析。
Ann Med. 2022 Dec;54(1):108-120. doi: 10.1080/07853890.2021.2012589.
6
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.格卡瑞韦/哌仑他韦治疗初治慢性 HCV 基因型 1-6 且代偿期肝硬化患者 8 周:EXPEDITION-8 试验。
J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2.
7
Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.对于一名丙型肝炎病毒3型患者,在其接受glecaprevir/pibrentasvir治疗失败且对NS3和NS5A产生耐药性后,使用glecaprevir/pibrentasvir联合索磷布韦和利巴韦林进行成功的持续再治疗。
Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.
8
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.格卡瑞韦哌仑他韦联合治疗丙型肝炎病毒的简化监测:一项随机非劣效性试验。
J Hepatol. 2020 Mar;72(3):431-440. doi: 10.1016/j.jhep.2019.10.010. Epub 2019 Oct 23.
9
Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.按需使用 glecaprevir 和 pibrentasvir 成功治疗弥漫性大 B 细胞淋巴瘤患者 R-CHOP 期间丙型肝炎 flares:一例报告。
BMC Infect Dis. 2021 Apr 27;21(1):389. doi: 10.1186/s12879-021-06091-x.
10
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.8 周格卡瑞韦哌仑他韦在初治代偿期肝硬化患者中的真实世界临床应用
Adv Ther. 2020 Sep;37(9):4033-4042. doi: 10.1007/s12325-020-01449-0. Epub 2020 Aug 4.

引用本文的文献

1
Findings on In Vitro Transporter-Mediated Drug Interactions and Their Follow-Up Actions for Labeling: Analysis of Drugs Approved by US FDA between 2017 and 2021.体外转运体介导的药物相互作用研究结果及其标签后续行动:对2017年至2021年美国食品药品监督管理局批准药物的分析
Pharmaceutics. 2022 Sep 29;14(10):2078. doi: 10.3390/pharmaceutics14102078.

本文引用的文献

1
Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.台湾地区泛基因型直接作用抗病毒药物治疗丙型肝炎病毒感染的真实世界疗效和安全性。
Sci Rep. 2021 Jun 29;11(1):13543. doi: 10.1038/s41598-021-93095-x.
2
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.格卡瑞韦/哌仑他韦在肝硬化丙型肝炎患者中安全有效:来自德国丙型肝炎注册中心的真实世界数据。
Liver Int. 2021 May;41(5):949-955. doi: 10.1111/liv.14829. Epub 2021 Mar 1.
3
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
在真实世界中,glecaprevir/pibrentasvir 治疗慢性丙型肝炎伴难治性因素患者的有效性和安全性:一项前瞻性多中心研究的综合分析。
Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3.
4
A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis.一例glecaprevir/pibrentasvir诱导的代偿期肝硬化患者严重高胆红素血症的病例报告。
Medicine (Baltimore). 2019 Sep;98(39):e17343. doi: 10.1097/MD.0000000000017343.
5
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.glecaprevir和pibrentasvir在肝功能受损的HCV阴性受试者中的药代动力学及安全性。
Eur J Clin Pharmacol. 2019 Feb;75(2):217-226. doi: 10.1007/s00228-018-2576-4. Epub 2018 Oct 19.
6
Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.钆塞酸增强磁共振成像预测丙型肝炎治疗中帕立瑞韦引起的高胆红素血症。
PLoS One. 2018 Apr 30;13(4):e0196747. doi: 10.1371/journal.pone.0196747. eCollection 2018.
7
EASL Recommendations on Treatment of Hepatitis C 2018.2018年欧洲肝脏研究学会丙型肝炎治疗推荐意见
J Hepatol. 2018 Aug;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9.
8
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.格卡瑞韦哌仑他韦联合比索那韦/利托那韦治疗代偿期肝硬化的成人慢性丙型肝炎病毒基因型 1、2、4、5 或 6 感染(EXPEDITION-1):一项单臂、开放标签、多中心 3 期临床试验。
Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14.
9
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.在健康的白种人、中国人和日本成年受试者中评估格卡瑞韦和哌仑他韦的药代动力学、安全性和耐受性。
J Clin Pharmacol. 2017 Dec;57(12):1616-1624. doi: 10.1002/jcph.959. Epub 2017 Aug 11.
10
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.glecaprevir和pibrentasvir治疗丙型肝炎病毒1型感染及既往直接抗病毒治疗12周。
Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10.